Henry Wu, MD
Nephrology · Mishawaka, INNPI 1891795670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $902, 5.9 times the $153 reported in 2019.
Across 161 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$573
- Abbott$324
- Fresenius USA Marketing, Inc.$319
- Bayer$301
- Otsuka America Pharmaceutical, Inc.$298
- Mallinckrodt Hospital Products Inc.$279
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,41694%
- Education$2296%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 32 | $573 |
| Abbott | 2 | $324 |
| Fresenius USA Marketing, Inc. | 18 | $319 |
| Bayer | 20 | $301 |
| Otsuka America Pharmaceutical, Inc. | 12 | $298 |
| Mallinckrodt Hospital Products Inc. | 6 | $279 |
| Amgen(2 entities) | 13 | $224 |
| Travere Therapeutics, Inc. | 8 | $178 |
| Vifor Pharma, Inc. | 6 | $154 |
| Aurinia Pharma U.S., Inc. | 7 | $135 |
| Calliditas Therapeutics US Inc. | 5 | $123 |
| GSK | 6 | $116 |
| Nxstage Medical, Inc. | 2 | $91 |
| Novartis | 4 | $78 |
| Lilly USA, LLC | 3 | $65 |
| Scpharmaceuticals Inc. | 2 | $48 |
| Ardelyx, Inc. | 2 | $48 |
| Akebia Therapeutics Inc | 2 | $47 |
| Kyowa Kirin, Inc. | 1 | $37 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Novo Nordisk | 1 | $26 |
| Merck | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$228
How this compares
$3,644 in reported general payments places this provider in the 75th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 12 | $227,292 |
| FarxigaDapagliflozin Propanediol | 210 | $170,637 |
| JardianceEmpagliflozin | 137 | $100,439 |
| KerendiaFinerenone | 34 | $22,972 |
| VeltassaPatiromer Calcium Sorbitex | 18 | $16,132 |
| EliquisApixaban | 17 | $15,332 |
| DapagliflozinDapagliflozin Propanediol | 19 | $9,866 |
| Potassium Citrate ErPotassium Citrate | 15 | $2,851 |
| Hydralazine Hcl | 154 | $1,946 |
| Midodrine Hcl | 23 | $1,286 |
| Doxazosin Mesylate | 63 | $1,211 |
| Calcitriol | 97 | $1,102 |
| Nifedipine ErNifedipine | 50 | $1,074 |
| Cinacalcet Hcl | 17 | $819 |
| Losartan Potassium | 141 | $806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $298 | $227,29212 claims |
| AstraZenecaFarxiga | $573 | $170,637210 claims |
| Boehringer IngelheimJardiance | $16 | $100,439137 claims |
| BayerKerendia | $301 | $22,97234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 238 nephrology providers in Indiana.
Other nephrology in Mishawaka
- Sudhir VyakaranamMishawaka$18K
- Lily SunioMishawaka$4K
- Swarupa EskapalliMishawaka$3K
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Narothama Reddy AeddulaEvansville$125K
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.